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for oligoclonal bands. Seven patients with SAH were recruited to clinical study 2, to enable further analysis of heme, which required more CSF (Table II in the online-only Data Supplement). Heme quantitation was performed using an in-house validated ultrahigh performance liquid chromatography technique; established immunoassays were used for hemopexin and albumin (online-only Data Supplement).
Postmortem Study
Postmortem brain tissue from SAH (n=7) and matched control (n=5) cases was obtained from the University Hospital Southampton National Health Service Foundation Trust as part of the UK Brain Archive Information Network. Tissue sections were selected close to the bleed; so, anatomic region varied in individual cases. The mean SAH-to-death interval was 16 days (range, 11-25 days); further characteristics are available in the online-only Data Supplement. CD91 and iron were analyzed by immunohistochemistry and Perls staining, respectively (more details are available in the online-only Data Supplement).
Statistical Analysis
The distribution of each data set was assessed, and parametric or nonparametric tests were used accordingly, as indicated in the text. Statistical tests were conducted at the 5% 2-sided significance level using SPSS version 21.
Results

Hemopexin Is Mainly Produced Intrathecally in Control CSF
The CSF hemopexin reference range as determined by ELISA was 12.3 to 32.6 μg/mL; the mean concentration was 22.4 μg/mL. There was no sex difference (mean, 21.5 and 24.6 μg/mL in women and men, respectively; P=0.23, unpaired t test). A well-established and accepted technique to determine intrathecal synthesis of blood-derived proteins similar to albumin is the intrathecal index, defined as the CSF/serum ratio of hemopexin (Q hemopexin ) divided by the CSF/serum ratio of albumin (Q albumin ). 6 Albumin is a plasma protein that is not synthesized in the brain and is wholly derived from plasma via diffusion across the blood-brain barrier (BBB). With a molecular weight of 69 kDa and a molecular size of 25.6 Å, albumin has the appropriate biophysical parameters to act as a reference protein for the diffusion of hemopexin across the BBB (hemopexin: molecular weight, 68 kDa and molecular size, 36 Å). Q hemopexin was significantly greater than Q albumin (P<0.0001, Wilcoxon signed-rank test; Figure 1A) ; the intrathecal index (Q hemopexin /Q albumin ) was 10.5. Thus, the vast majority of hemopexin is produced intrathecally in control individuals, with only about one tenth being derived from the circulation.
CD91-Hemopexin-Heme Scavenging System Is Present and Active in Human Brain After SAH
CD91 immunohistochemistry on human brain tissue revealed expression in neurons and glia ( Figure 1B) . Uptake of hemehemopexin complexes leads to intracellular deposition of heme's iron moiety. 7 Perls staining to quantify iron deposition revealed a significantly greater deposition of iron in 
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SAH versus control cases (P=0.028, Mann-Whitney test; Figure 1C ). Regardless of whether there was blood clot in the sections, iron deposition significantly correlated with CD91 (Spearman r=0.79; P=0.0025; Figure 1D ), indicating that the CD91-hemopexin system actively scavenges heme after SAH.
Increased CSF Hemopexin After SAH Is Associated With Poor Outcome
After SAH, CSF hemopexin had a bimodal distribution; in 30% of patients (n=9/30), CSF hemopexin was above the reference range (Figure 2A) Figure 2B ). The bloodderived fraction could have 2 sources: the initial bleed itself and increased transfer from the circulation via a more permeable BBB. If the initial bleed was the predominant source of plasma proteins in the CSF, one would expect a significant negative correlation between sampling time and Q albumin ; however, this was not present (Pearson correlation coefficient=−0.045; P=0.826). In support of increased transfer from the circulation across a compromised BBB, there was a significant increase in BBB permeability in the high CSF hemopexin group as evidenced by a raised Q albumin (2-fold; P=0.033, unpaired t test; Figure 2C ). Hence, the predominant source of increased CSF hemopexin associated with poor outcome was intrathecal, with some derived from the circulation.
Saturation of Heme-Hemopexin Uptake After SAH
The high CSF hemopexin suggested saturation of hemehemopexin uptake. To look for this, SAH CSF was examined for the presence of heme-hemopexin complexes. Sufficient CSF from 1 patient in clinical study 1 was available for ultrahigh performance liquid chromatography analysis to detect bound heme; in this patient, who had a high CSF hemopexin level (98.5 μg/mL), a substantial amount of heme was bound to hemopexin and albumin ( Figure 3A , inset; Figure I in the online-only Data Supplement, peak at 4.5 minutes). In 7 other patients with high-grade SAH, with repeated CSF sampling (clinical study 2), bound heme was found at all time points, confirming rapid saturation of heme-hemopexin uptake, up to at least day 13 after SAH ( Figure 3A ). 
Free Heme After SAH
In the same 7 patients from clinical study 2, unbound heme was assayed by performing ultrahigh performance liquid chromatography before and after adding recombinant hemopexin to the CSF sample, the difference in area-under-thecurve representing unbound heme. All samples tested showed an increase in the peak for bound heme when preincubated with recombinant hemopexin, indicating the presence of free, unbound heme in the CSF, up to at least day 13 after SAH ( Figure 3B ).
Evidence for Efflux of Free Heme From the Brain
After SAH, a small and lipophilic molecule, such as heme, can theoretically diffuse out of the brain into the bloodstream down a steep concentration gradient across the BBB. There was a significant drop in serum hemopexin after SAH (mean, 0.72 mg/mL in controls versus 0.55 mg/mL after SAH; P=0.002, unpaired t test; Figure 3C ). This decrease was confined to patients with the highest Q albumin , in whom BBB permeability to heme would be the highest (P=0.04, unpaired t test; Figure 3D ).
Discussion
This is the first study to characterize the intrathecal CD91-hemopexin system in control individuals and after SAH. Intrathecal production is likely to be the main source of CSF hemopexin, with only about one tenth being derived from the circulation. Hemopexin is known to be produced within the brain, and CD91 is not expressed by cerebral endothelium 5, 8 ; so, receptor-mediated transport of hemopexin into the brain is unlikely but cannot be excluded. Still, CSF hemopexin was 10-fold lower compared with serum, suggesting that the brain has a comparatively lower heme-binding capacity.
After SAH, the CD91-hemopexin scavenging system is active in the brain because CD91 significantly correlated with iron deposition. CSF hemopexin had a bimodal pattern after SAH. Despite similar bleed size and severity, high CSF hemopexin patients had a poorer outcome, with higher delayed cerebral ischemia rates and higher mRS scores. This needs replication because CSF hemopexin may be of clinical utility as a prognostic marker. The Glasgow Outcome Scale was not significantly different between individuals with normal and high CSF hemopexin; however, such a discrepancy between Glasgow Outcome Scale and mRS has been noted after SAH before 9 and may be related to the higher number of scoring categories of the mRS being able to differentiate neurological sequelae with greater subtlety. In addition, mRS is a stroke outcome scale, more akin to SAH, whereas Glasgow Outcome Scale was developed as a scale for use in traumatic head injury.
The elevation of CSF hemopexin, and its relationship with outcome, is intriguing, and the mechanism is not clear. Hemopexin has been reported to be neuroprotective, 10 and therefore, CSF hemopexin is not assumed to be toxic. 
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However, it is also possible that when CSF hemopexin is too high, it becomes deleterious by binding heme, preventing its efflux from the brain and resulting in intracellular heme/iron overload, which may be toxic to neurons/glia. Another potential explanation is that events after SAH, such as saturation of heme-hemopexin uptake or inflammation, result in high CSF hemopexin and poor outcome, which are, therefore, indirectly associated. Clearly, further mechanistic studies are needed. CSF hemopexin had 2 sources: (1) accumulation from an intrathecal origin (as indicated by a 3-fold rise in the hemopexin intrathecal index) and (2) increased transfer from the circulation (supported by a 2-fold higher Q albumin ). Accumulation of brain-derived hemopexin after SAH may occur as a result of increased synthesis or decreased CD91-mediated scavenging. Increased synthesis may be secondary to the host inflammatory response because the hemopexin promoter is interleukin-6 responsive, 11 and interleukin-6 levels are elevated in SAH CSF. 12 Decreased CD91-mediated scavenging may be because of plateauing in heme-hemopexin uptake because heme and hemopexin were detected simultaneously in the CSF. Also, because CD91 has multiple ligands, it is possible that there is competition for CD91 from other ligands, such as ApoE. 13 Interestingly, CSF ApoE is known to decrease after SAH, 13 and low CSF ApoE associates with a poor outcome, 
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Figure I The CD91 system is saturated following SAH. UPLC trace at 415nm to identify bound heme related peaks from the CSF of a patient with high CSF Hpx; a substantial peak for Hpx and albumin bound heme is observed at 4.5min
Supplemental Methods
Clinical study 1 (Main study)
Admission computed tomography (CT) images were available for 20 patients, and quantitative analysis of blood clot average voxel radiodensity, as a surrogate of bleed size, was performed as previously described. 1 Clinical information regarding delayed cerebral ischaemia (DCI) was available for 26 patients. Clinical DCI was defined as the onset of a new focal neurological deficit or a two point drop in the Glasgow Coma Score in the absence of rebleeding, hydrocephalus, metabolic abnormalities or seizure activity. patients with SAH to perform derivative spectrophotometry for quantification of Hb as previously described, 1 and from one patient to perform heme measurements using ultra-high performance liquid chromatography (UPLC) as described below.
Clinical study 2
Clinical study 1 did not produce large enough CSF volumes for UPLC analysis of heme concentration which needed 400uL. Therefore, in a second study, serial CSF samples were obtained from seven additional patients with high grade SAH (Fisher grade III-IV) admitted to the Southampton centre, requiring prolonged external ventricular drainage, under research approval 12/SC/0666. The characteristics of these patients are shown in Table II in the online-only Data Supplement.
Ultra-high performance liquid chromatography (UPLC).
Size-exclusion UPLC was used to separate components by size. Peaks were monitored at 415 nm wavelength to exclude nonheme related peaks while differentiating bound heme from free and bound Hb. Heme quantitation was performed by reading against a standard curve. A Hb standard solution was prepared from commercially-available lyophilized human Hb (Sigma). This was reconstituted to 1 g/L in diluent (9 g/L NaCl, 10 mM EDTA). The concentration of the standard Hb solution was verified independently by spectrophotometric quantitation of derivatized heme at 570 nm using a Hemocue™ (Hemocue, Sweden). A concentration series of 9 data points from 0 to 1 mg/ml was prepared from the standard solution and measured at 415 nm on the UPLC. Accuracy of the standard curve was determined to be 3.3% using a Hb control. CSF samples were saturated with 250 µg/ml Hpx (Sigma) to detect total heme, or measured neat to detect bound heme. 50µl of each sample was loaded onto the UPLC column using a running buffer consisting of 50 mM Tris and 150 mM NaCl, at pH 7.5. Absorbance was measured at 415 nm and the area under the curve calculated and quantitated against the standard curve. Free heme was calculated by subtracting bound heme from total heme. Each assay run was controlled using an in-house hemoglobin-haptoglobin standard measured at three concentration levels; 200 µg/ml, 10 µg/ml and 1 µg/ml to cover the dynamic range of the assay, with precision of 1.9%, 16.1% and 36.3% respectively.
Post-mortem study
Post-mortem formalin-fixed paraffin-embedded tissue from a different set of SAH (n=7) 1:1000 dilution overnight, followed by incubation with biotin-conjugated secondary antibody.
Development was performed using the ABC method and 0.05% 3,3`-diaminobenzidine.
Sections were finally counterstained with haematoxylin, dehydrated and mounted in DePeX.
Sections incubated in the absence of the primary antibody were included as negative controls, and all sections were immunolabelled together to ensure comparability of staining.
Quantification. For each case, ten images were digitally acquired from grey matter in a ribbon following the most prominent sulcus in each section, using a camera mounted on a light microscope at magnification x20. The images were analysed with Image J (version 1.47, NIH US) to obtain a protein load defined as the percentage area stained of total area examined (%). Perls staining severity index was quantified as described previously.
